Intervention not reported
50% reduction of tumour sizea · people with TSC
The intervention leads to higher 50% reduction of tumour sizea (high certainty).
1 finding from 1 review
- RR 24.7 [3.5, 173.4]2 studies · 162 participantsHigh
Findings
What do systematic reviews say?
19 questions · 19 findings · 2 reviews · Cystic Fibrosis and Genetic Disorders · Headline outcomes only
No studies found 5 · 26.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 10.5%Moderate 8 · 42.1%High 4 · 21.1%
Intervention not reported
Frequency of seizure · people with TSC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Creatinine level · people with TSC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
FEV1/FVC ratio · people with TSC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Outcomes relevant to participants' well‐being · people with TSC
1 finding from 1 review
- no estimate extracted1 study · 62 participantsLow
Intervention not reported
Adverse events · people with TSC
The intervention probably leads to higher adverse events (moderate certainty).
1 finding from 1 review
- RR 1.72 [1.1, 2.67]3 studies · 277 participantsModerate
Intervention not reported
Response to skin lesionsb · people with TSC
The intervention leads to higher response to skin lesionsb (high certainty).
1 finding from 1 review
- RR 5.8 [2.3, 14.5]2 studies · 224 participantsHigh
Intervention not reported
Frequency of seizure · people with TSC
The intervention probably leads to higher frequency of seizure (moderate certainty).
1 finding from 1 review
- RR 5.31 study · 366 participantsModerate
Intervention not reported
Number of participants with an increased creatinine level · people with TSC
The intervention probably leads to lower number of participants with an increased creatinine level (moderate certainty).
1 finding from 1 review
- RR 0.161 study · 118 participantsModerate
Intervention not reported
FEV1/FVC ratio · people with TSC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Outcomes relevant to participants' well‐being · people with TSC
1 finding from 1 review
- no estimate extracted1 study · 42 participantsLow
Intervention not reported
Adverse events · people with TSC
The intervention leads to higher adverse events (high certainty).
1 finding from 1 review
- RR 1.095 studies · 680 participantsHigh
Intervention not reported
50% reduction in tumour size · people with TSC
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Response to skin lesion · people with TSC
The intervention leads to higher response to skin lesion (high certainty).
1 finding from 1 review
- RR 2.72 [1.76, 4.18]2 studies · 187 participantsHigh
Summary of findings ‐ AZLI vs placebo
FEV1 % predicted: relative change from baseline · adults and children with CF
1 finding from 1 review
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 99 participantsModerate
Summary of findings ‐ AZLI vs placebo
Time to next exacerbation · adults and children with CF
1 finding from 1 review
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 100 participantsModerate
Summary of findings ‐ AZLI vs placebo
Participants hospitalised for respiratory exacerbation · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes onlyRR 0.88 [0.53, 1.45]1 study · 100 participantsModerate
Summary of findings ‐ AZLI vs placebo
Adverse events (AEs) (1 or more events) · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).
1 finding from 1 review
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes onlyRR 1.08 [0.98, 1.19]1 study · 100 participantsModerate
Summary of findings ‐ AZLI vs placebo
All‐cause mortality · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes onlyRR 5.41 [0.27, 109.87]1 study · 100 participantsModerate